Lakewood-Amedex Biotherapeutics Inc. (LABT) Balance Sheet
LABT balance sheet, 2025
December 31, 2025 · U.S. dollars$481,598 assets = $2.4M liabilities + −$2.0M equity
Liabilities exceed assets: shareholders’ equity is negative (−$2.0M).
Both columns are drawn to the same scale: what LABT owns equals what it owes plus shareholders’ equity. Hover a block for its value.
LABT financial health
Descriptive bands, not a rating. Fiscal 2025.
LABT balance sheet trends, 2023–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $6.9M2023 | $481,5982025 | −73.6%/yr | |
| Total liabilities | $2.3M2023 | $2.4M2025 | +2.3%/yr | |
| Shareholders’ equity | $4.6M2023 | −$2.0M2025 | — | |
| Cash & short-term investments | $6.4M2023 | $236,4002025 | −80.8%/yr | |
| Working capital | $4.4M2023 | −$2.1M2025 | −$6.5M | |
| Book value per share | $6.522023 | −$1.412025 | — | |
| Current ratio | 3.142023 | 0.132025 | −3.01 | |
| Shares outstanding | 700K2023 | 1.4M2025 | +41.1%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
LABT assets
LABT liabilities and equity
LABT debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
LABT balance sheet
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Assets | |||
| Cash & short-term investments | $236,400 | $681,098 | $6.4M |
| Cash & equivalents | $236,400 | $681,098 | $2.5M |
| Short-term investments | — | $0 | $3.9M |
| Receivables | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 |
| Other current assets | $68,989 | $92,883 | $90,089 |
| Total current assets | $305,389 | $773,981 | $6.5M |
| Property, plant & equipment (net) | $168,077 | $288,053 | $404,801 |
| Goodwill & intangible assets | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 |
| Other non-current assets | $8,132 | $8,547 | $8,547 |
| Total assets | $481,598 | $1.1M | $6.9M |
| Liabilities | |||
| Accounts payable | $381,041 | $166,467 | $499,066 |
| Short-term debt | $1.6M | — | — |
| Total current liabilities | $2.4M | $500,628 | $2.1M |
| Long-term debt | $0 | $0 | $0 |
| Lease obligations | $160,341 | $272,862 | $378,884 |
| Other long-term liabilities | $41,035 | $160,342 | $272,862 |
| Total liabilities | $2.4M | $660,970 | $2.3M |
| Shareholders' equity | |||
| Common stock & paid-in capital | $704 | — | — |
| Retained earnings (deficit) | −$53.4M | −$49.5M | −$44.6M |
| Total shareholders' equity | −$2.0M | $409,611 | $4.6M |
| Key figures | |||
| Total debt | $1.7M | — | — |
| Net cash (debt) | −$1.4M | — | — |
| Working capital | −$2.1M | $273,353 | $4.4M |
| Tangible book value | −$2.0M | $409,611 | $4.6M |
| Book value per share | −$1.41 | $0.59 | $6.52 |
| Shares outstanding | 1.4M | 700K | 700K |
| Current ratio | 0.13 | 1.55 | 3.14 |
| Quick ratio | 0.10 | 1.36 | 3.10 |
| Equity / assets | −407.9% | 38.3% | 66.1% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Dec '24 | |
|---|---|---|---|---|---|
| Assets | |||||
| Cash & short-term investments | $4.6M | $11,709 | $236,400 | $658,410 | $681,098 |
| Cash & equivalents | $2.6M | $11,709 | $236,400 | $658,410 | $681,098 |
| Short-term investments | $2.0M | — | — | — | $0 |
| Receivables | $4,526 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $255,999 | $38,917 | $68,989 | $119,794 | $92,883 |
| Total current assets | $4.8M | $50,626 | $305,389 | $778,204 | $773,981 |
| Property, plant & equipment (net) | $106,889 | $8,066 | $168,077 | $198,367 | $288,053 |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $7,821 | $137,651 | $8,132 | $8,547 | $8,547 |
| Total assets | $5.0M | $196,343 | $481,598 | $985,118 | $1.1M |
| Liabilities | |||||
| Accounts payable | $165,942 | $547,829 | $381,041 | $278,774 | $166,467 |
| Short-term debt | $101,619 | $1.7M | $1.6M | $1.6M | — |
| Total current liabilities | $628,926 | $3.0M | $2.4M | $2.2M | $500,628 |
| Long-term debt | $0 | $0 | $0 | $0 | $0 |
| Lease obligations | $101,619 | $131,339 | $160,341 | $189,018 | $272,862 |
| Other long-term liabilities | $0 | $10,295 | $41,035 | $71,433 | $160,342 |
| Total liabilities | $628,926 | $3.0M | $2.4M | $2.3M | $660,970 |
| Shareholders' equity | |||||
| Common stock & paid-in capital | $217 | $704 | $704 | $704 | — |
| Retained earnings (deficit) | −$68.6M | −$54.3M | −$53.4M | −$52.6M | −$49.5M |
| Total shareholders' equity | $4.3M | −$2.8M | −$2.0M | −$1.3M | $409,611 |
| Key figures | |||||
| Total debt | $101,619 | $1.8M | $1.7M | $1.7M | — |
| Net cash (debt) | $4.5M | −$1.7M | −$1.4M | −$1.0M | — |
| Working capital | $4.2M | −$3.0M | −$2.1M | −$1.4M | $273,353 |
| Tangible book value | $4.3M | −$2.8M | −$2.0M | −$1.3M | $409,611 |
| Book value per share | $3.05 | −$4.06 | — | −$0.91 | $0.29 |
| Shares outstanding | 1.4M | 700K | — | 1.4M | 1.4M |
| Current ratio | 7.70 | 0.02 | 0.13 | 0.36 | 1.55 |
| Quick ratio | 7.30 | 0.00 | 0.10 | 0.30 | 1.36 |
| Debt / equity | 0.02 | — | — | — | — |
| Equity / assets | 87.3% | −1,447.3% | −407.9% | −128.5% | 38.3% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed December 31, 2025); data from EODHD.
LABT financial position
At the end of fiscal 2025 (December 31, 2025), Lakewood-Amedex Biotherapeutics had total assets of $0.5 million (down 55.0% from a year earlier), total liabilities of $2.4 million and shareholders' equity of -$2.0 million. It held $0.2 million in cash and short-term investments against $1.7 million of debt, net debt of $1.4 million. Its current ratio was 0.13. In the latest quarter (ended June 30, 2026) total assets were $5.0 million and equity $4.3 million.
Related: LABT income statement, LABT cash flow statement, LABT key metrics. See the LABT stock overview for the latest quote and news.
LABT balance sheet FAQ
What are Lakewood-Amedex Biotherapeutics's total assets?
Lakewood-Amedex Biotherapeutics reported total assets of $0.5 million at the end of fiscal 2025 (December 31, 2025), compared with $1.1 million a year earlier.
How much debt does Lakewood-Amedex Biotherapeutics have?
Lakewood-Amedex Biotherapeutics had $1.7 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was —.
How much cash does Lakewood-Amedex Biotherapeutics have?
Lakewood-Amedex Biotherapeutics held $0.2 million in cash and short-term investments at the end of fiscal 2025; with $1.7 million of debt that is net debt of $1.4 million.
What is Lakewood-Amedex Biotherapeutics's book value?
Lakewood-Amedex Biotherapeutics's shareholders' equity (book value) was -$2.0 million at the end of fiscal 2025, or −$1.41 per share.
What is Lakewood-Amedex Biotherapeutics's current ratio?
Lakewood-Amedex Biotherapeutics had current assets of $0.3 million and current liabilities of $2.4 million, a current ratio of 0.13 (current liabilities exceed current assets).